Thank you for joining us. I am your host Yohemy Auerbach at CRWE Newswire Stocks to watch. Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings. Lymphoma is a general term for a group of cancers that originate in the lymphatic system. According to the National Cancer Institute, Estimated 8,830 new cases and 1,300 deaths from Hodgkin lymphoma in the United States in 2011. Seattle Genetics has U.S. and Canadian commercialization rights for adcetris. The company expects to make ADCETRIS available to patients in the next week. Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Yohemy Auerbach.
